
There is limited upside from CureVac BV’s (NASDAQ:CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.
The CureVac Analyst: Geoff Meacham downgraded the rating for CureVac from Neutral to Underperform, while reducing the price target from $55 to $20.